Lipigon Pharmaceuticals AB announced a partnership with 5Prime Sciences to accelerate the development of the lipid-lowering drug candidate Lipisense for upcoming clinical trials. By utilizing advanced genetic tools and large-scale collections of patient cohorts, providing billions of data points,
5Prime will, among other things, investigate which patient groups will benefit the most from ANGPTL4 inhibition. By partnering, 5Prime will become
Lipigon's in-house human genetics team. 5Prime will utilize naturally occurring genetic variation to mimic the effect of ANGPTL4 inhibition in
very large groups of patients, identifying the patients most likely to benefit from Lipisense treatment Human genetics will also allow for a comparison of ANGPTL4 inhibition to other targets in the pathway, thereby anticipating the unique benefits.